I'm LongbridgeAI, I can summarize articles.MetaVia reported a widened Q2 FY26 net loss of $5.3 million, or $0.90 per share, compared to a $4 million loss in the prior year. R&D expenses surged 52.17% to $3.48 million due to DA-1726 development costs, while total operating expenses rose 25.2%. Cash reserves increased to $12.6 million, sufficient for operations through 2026. Topline data for DA-1726 Phase 1 Part 3 is expected in Q4 2026.
- Metavia posts Q2 net loss of USD 5.3 million, or USD 0.90 per share, widening from a USD 4 million loss a year earlier. * R&D expenses rise 52.17% to USD 3.48 million, driven by higher direct costs tied to DA-1726 development. * Total operating expenses climb 25.2% to USD 5.39 million, while G&A edges down 3.74% to USD 1.91 million. * Cash and cash equivalents increase to USD 12.6 million as of June 30 from USD 10.3 million at Dec. 31; cash seen funding operations through 2026. * All active patients reached 48 mg and 64 mg in DA-1726 Phase 1 Part 3; 16-week topline data expected in Q4 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY20934) on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)